New Research Findings May Bring Breakthrough For Scleroderma Patients PDF Print E-mail
Monday, 01 October 2012 22:13
Research presented at the European Academy of Dermatology and Venereology in Prague, Czech Republic, suggests that inhibition of the SMAD protein may be a viable therapeutic target in Scleroderma patients.

This finding builds on previous research by presenter and lead researcher Donal O'Kane and colleagues showing that epidermal to mesenchymal transition (EMT) occurs in the skin of Scleroderma patients. This is most likely induced by high levels of the inflammatory cytokines transforming growth factor (TGF)-β and tumor necrosis factor (TNF)-α in sclerodermatous skin, and contributes directly to cutaneous fibrosis.

In the current study, O'Kane and team showed that SMAD inhibition weakens or reverses EMT in a normal human epidermal keratinocyte cell line. EMT was induced in the cells by the introduction of high levels of TGF-β and TNF-α to mimic conditions present in sclerodermatous human skin.

These findings could prove a real breakthrough for Scleroderma patients, as currently available treatments for Scleroderma are limited and often ineffective.

"At the minute because no treatments work effectively in clinical practice my feeling is that that's because they focus on fibrosis in the dermis as opposed to what predates that," O'Kane told medwireNews.

"The novel part of this EMT is we think that's before the fibrotic phase," he added, "so it gives a total new approach to the treatment of fibrotic disease and potentially will raise a lot more treatments as well."

To continue reading the full article, click here.

Source: Albert, H. (2012), "New treatment target brings hope for scleroderma patients"; News-medical.net;

 
More articles :

» Calcinosis

Background:The Foundation has recently received some feedback from some members of the public asking for more information regarding the condition known as Calcinosis. As part of our efforts we sought to provide a brief, yet informative insight into...

» Erectile Dysfunction Drug Could Improve Raynaud’s Symptoms Associated with Scleroderma

Adding tadalafil (Cialis®; Adcirca®) to the treatment of people with can improve ’s phenomenon symptoms and heal and prevent hand and finger associated with it, according to research presented this week at the American College of Rheumatology...

» Do You Need To Alter Your Diet?

According to Chrissy Carroll, a registered dietitian and certified personal trainer with the , Scleroderma can present differently in each affected person, and diet recommendations are typically targeted toward specific symptoms. She indicated that...

» Natural Alternatives for Dealing With Scleroderma

In a recent article, it was noted that conventional medicine attempts to treat the symptoms of with immunosuppressant drugs, NSAIDS and , but has no cure and little advice for prevention. It was noted however, that the world of natural healing has...

» Scleroderma-Related PAH: The Need for Early Diagnosis and Treatment

Pulmonary arterial hypertension (PAH) associated with scleroderma (systemic sclerosis) is an aggressive disorder with a poor prognosis. Effective therapies are available for PAH but patients with scleroderma-associated PAH have a poorer response to...

» Long-Term Outcomes of Scleroderma Renal Crisis

In a previous study. researchers sought to describe the medical history of a group of patients with Scleroderma Renal Crisis who had been treated with ACE inhibitors. The following is essentially a summary of that study, which was conducted by...